Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

W. Kievit; N. van Herwaarden; F. van den Hoogen; R. van Vollenhoven; H. Bijlsma; B. van den Bemt; A. van der Maas; A. den Broeder

doi:10.1016/j.jval.2015.09.2324

Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

W. Kievit
, N. van Herwaarden
, F. van den Hoogen
, R. van Vollenhoven
, H. Bijlsma
, B. van den Bemt
, A. van der Maas
, A. den Broeder

pre-AMC

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	A647-A648
Journal	Value in health
Volume	18
Issue number	7
DOIs	https://doi.org/10.1016/j.jval.2015.09.2324
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.1016/j.jval.2015.09.2324

Cite this

Kievit, W., van Herwaarden, N., van den Hoogen, F., van Vollenhoven, R., Bijlsma, H., van den Bemt, B., van der Maas, A., & den Broeder, A. (2015). Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. Value in health, 18(7), A647-A648. https://doi.org/10.1016/j.jval.2015.09.2324

@article{37cd553babc244e685112099566e86dc,

title = "Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients",

author = "W. Kievit and \{van Herwaarden\}, N. and \{van den Hoogen\}, F. and \{van Vollenhoven\}, R. and H. Bijlsma and \{van den Bemt\}, B. and \{van der Maas\}, A. and \{den Broeder\}, A.",

year = "2015",

doi = "10.1016/j.jval.2015.09.2324",

language = "English",

volume = "18",

pages = "A647--A648",

journal = "Value in health",

issn = "1098-3015",

publisher = "Elsevier Limited",

number = "7",

}

Kievit, W, van Herwaarden, N, van den Hoogen, F, van Vollenhoven, R, Bijlsma, H, van den Bemt, B, van der Maas, A & den Broeder, A 2015, 'Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients', Value in health, vol. 18, no. 7, pp. A647-A648. https://doi.org/10.1016/j.jval.2015.09.2324

Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. / Kievit, W.; van Herwaarden, N.; van den Hoogen, F. et al.
In: Value in health, Vol. 18, No. 7, 2015, p. A647-A648.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients

AU - Kievit, W.

AU - van Herwaarden, N.

AU - van den Hoogen, F.

AU - van Vollenhoven, R.

AU - Bijlsma, H.

AU - van den Bemt, B.

AU - van der Maas, A.

AU - den Broeder, A.

PY - 2015

Y1 - 2015

U2 - 10.1016/j.jval.2015.09.2324

DO - 10.1016/j.jval.2015.09.2324

M3 - Article

C2 - 26533629

SN - 1098-3015

VL - 18

SP - A647-A648

JO - Value in health

JF - Value in health

IS - 7

ER -